For the first nine months of 2011, the Company reported revenues of $40.4 million, an increase of 20% compared to revenues of $33.7 million for the first nine months of 2010. Net loss for the first nine months of 2011 was $52.0 million or $0.52 per share, as compared to net loss of $98.8 million, or $1.44 per share for the same period of 2010.
Gross margin for the first nine months of 2011 was 63% of revenues as compared to gross margin of 59% for the first nine months of 2010. This improvement is associated with a larger installed base of MassARRAY systems, which resulted in increased consumables sales, as well as higher average selling prices for our MassARRAY 4 system and increased sales volumes in our diagnostics business.
Total operating expenses for the first nine months of 2011 were $77.8 million, as compared to total expenses of $118.8 million for the same period in 2010. This reduction was primarily the result of a decrease in litigation settlement expense of $48.8 million for the first nine months of 2010, which did not recur in 2011.
Research and development expenses increased to $40.4 million for the first nine months of 2011 from $32.9 million during the same period in 2010. The incremental expense is related primarily to our obligations under additional intellectual property licensing and collaboration agreements, costs associated with the expansion of the Sequenom CMM laboratory,
|SOURCE Sequenom, Inc.|
Copyright©2010 PR Newswire.
All rights reserved